US Pharma MarketingFDA approves Takeda, Protagonist drug as first treatment for rare blood disorder
FDA approved Takeda & Protagonist Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and…
The FDA approved rusfertide, a new drug from Takeda and Protagonist Therapeutics to treat a rare blood disease.
Rusfertide, which will be branded as Mimrylo, can now be prescribed for polycythemia vera, a disease in ...
Source: Endpoints News